The treatment of multiple myeloma is highly personalized at John Theurer Cancer Center, part of Hackensack University Medical Center in New Jersey. We are one of the few treatment centers in the nation offering a full team of specialized experts in the care of patients with all stages of multiple myeloma. If you have multiple myeloma, we carefully assess the stage and biology of your disease to match you with the best treatment, or to customize a surveillance program for you if you do not yet need therapy. When you come to us for your care, you’ll see the same physician at every visit who gets to know you and your family, is available to address your questions and concerns, and provides a personal level of care that can be hard to find elsewhere.
While two cases of multiple myeloma can look the same under the microscope and may appear to be the same disease, we now know that there are more than five different subsets of myeloma, each with its own biological features and behavior. That’s why we don’t take a one-size-fits-all approach to myeloma treatment. When you come to John Theurer Cancer Center for multiple myeloma care, we’ll perform a comprehensive molecular analysis of your cancer to determine its subtype, and match you with the most appropriate therapy. This “precision medicine” approach ensures that you receive the therapy that is best suited for the biology of your cancer, offering the greatest chance of success.
Our doctors are leaders in myeloma research. Their research efforts have resulted in some of the most promising treatments for myeloma used today, including bortezomib (Velcade), lenalidomide (Revlimid), and carfilzomib (Kyprolis). In addition, our team participated in the development of four myeloma therapies just approved over the last few years: daratumumab (Darzalex), elotuzumab (Empliciti), ixazomib (Ninlaro), and panobinostat (Farydak). What does this mean for you? It means your treatment team is not only knowledgeable about, but involved in the development of the very latest therapies for your disease—and therefore best equipped to provide you with the most advanced solutions.
John Theurer Cancer Center has one of the largest bone marrow or stem cell transplantation programs in the country for multiple myeloma, performing over 250 transplants a year. Our program features physicians whose primary focus is transplantation for multiple myeloma. We also perform more allogeneic transplants (using stem cells from a healthy donor) for multiple myeloma than any other center in our region. Our research has a strong focus on reducing the complications of transplantation and also lowering the risk of recurrence. For example, we are the first team in the world to combine checkpoint inhibitors (drugs that work by inhibiting the proteins cancer cells use to evade detection by the immune system) after transplantation, at a time where the newly reset immune system has the best opportunity to eliminate residual cancer cells.
Some people have diseases that have the potential to turn into multiple myeloma. These “precursor” disorders include smoldering multiple myeloma and MGUS (monoclonal gammopathy of undetermined significance). If you were diagnosed with one of these disorders, you may have been surprised because they don’t cause any symptoms. Our doctors take a conservative approach to treating patients with smoldering multiple myeloma and MGUS. We’ll monitor you and let you know if or when you may benefit from treatment. We also offer clinical trials assessing immunological factors and other predictors of the best time to start treatment.
The Institute for Multiple Myeloma will be located in a state-of-the art research facility at the Hackensack Meridian Health Interprofessional Health Sciences Campus in Nutley and Clifton, NJ, and led by founding director, Dr. David Siegel, chief of the Multiple Myeloma Division at John Theurer Cancer Center. Under the leadership of Dr. Siegel, and alongside hematology experts like Dr. André Goy, chairman and executive director, division chief of Lymphoma at John Theurer Cancer Center, the Institute will focus on driving innovative research, and continuing the development of precision medicine for each patient.
We bring together all the multiple myeloma experts you may need—offering dedicated highly specialized providers trained at the world’s best academic medical centers—from hematology/medical oncology, immunology, stem cell transplantation, infectious diseases, pathology, radiation oncology, orthopedics, and nursing to provide you with a tailored plan of care based on the specific features of your disease and your personal condition. Our goal is to treat your myeloma while taking into account all physical, functional, emotional, and quality of life aspects of your disease. We don’t just care for you, but about you. In fact, according to Press-Ganey surveys, 99 percent of our patients report satisfaction with their care.
The following is a list of myeloma clinical trials at this center.
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
The following is a listing of clinical trials for patients with Smoldering Myeloma.
The following is a listing of clinical trials for patients with Monoclonal Gammopathy of Undetermined Significance (MGUS).
SparkCures is working closely with John Theurer Cancer Center to provide the most up-to-date information on their myeloma program, specialists and clinical trials. Use the buttons above to claim this as your Home Center or add it to your List of Favorites.
Learn more about how we work with myeloma centers